Search results for "Dyslipidemias"

showing 10 items of 124 documents

No Improvement of High-Density Lipoprotein (HDL) Vasorelaxant Effect Despite Increase in HDL Cholesterol Concentration in Type 2 Diabetic Patients Tr…

2014

Abstract Context: High-density lipoproteins (HDLs) from type 2 diabetic patients are unable to counteract the inhibitory effect of oxidized low-density lipoproteins (ox-LDLs) on vasorelaxation. We hypothesized that glitazones, which improve glycemic control and dyslipidemia, could correct this abnormality. Objectives and Design: We compared the ability of HDL from controls (n = 12) and from type 2 diabetic patients before and after 6 months of treatment with either rosiglitazone (n = 11) or pioglitazone (n = 8) to counteract the inhibitory effect of ox-LDL on vasodilatation of rabbit aorta rings. Results: Rosiglitazone induced a decrease in hemoglobin A1c (7.7% ± 1.1% vs 9.8% ± 1.0%, P = .0…

Malemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryContext (language use)BiochemistryRosiglitazonechemistry.chemical_compoundEndocrinologyHigh-density lipoproteinInternal medicineDiabetes mellitusmedicineAnimalsHumansHypoglycemic AgentsThiazolidinedioneAortaAgedDyslipidemiasPioglitazoneCholesterolbusiness.industryCholesterol HDLBiochemistry (medical)Middle Agedmedicine.diseaseLipoproteins LDLVasodilationEndocrinologyDiabetes Mellitus Type 2chemistryFemaleThiazolidinedionesEndothelium VascularRabbitsLipoproteins HDLRosiglitazonebusinessPioglitazoneDyslipidemiamedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Obstructive sleep apnoea independently predicts lipid levels: Data from the European Sleep Apnea Database

2018

Background and objective: Obstructive sleep apnoea (OSA) and dyslipidaemia are independent risk factors for cardiovascular disease. This study investigates the association between OSA and plasma lipid concentrations in patients enrolled in the European Sleep Apnea Database (ESADA) cohort. Methods: The cross-sectional analysis included 8592 patients without physician-diagnosed hyperlipidaemia or reported intake of a lipid-lowering drug (age 50.1 ± 12.7 years, 69.1% male, BMI: 30.8 ± 6.6 kg/m2, mean apnoea–hypopnoea index (AHI): 25.7 ± 25.9 events/h). The independent relationship between measures of OSA (AHI, oxygen desaturation index (ODI), mean and lowest oxygen saturation) and lipid profil…

MaleobesityDatabases Factualcholesterol dyslipidemia hypoxia obesity sleep apnoeaGastroenterologyCohort Studieschemistry.chemical_compound0302 clinical medicineRisk FactorsHypolipidemic AgentsOxygen saturation (medicine)Sleep Apnea Obstructivemedicine.diagnostic_testSleep apneaMiddle AgedEuropeQuartileCardiovascular DiseasesCohortFemalelipids (amino acids peptides and proteins)AdultPulmonary and Respiratory Medicinemedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicinemedicineHumansTriglyceridesDyslipidemiashypoxiaCholesterolbusiness.industryCholesterol HDLdyslipidemiacholesterolCholesterol LDLta3121medicine.diseaseObesitynervous system diseasesrespiratory tract diseasesCross-Sectional Studies030228 respiratory systemchemistryLipid profilebusinesssleep apnoea030217 neurology & neurosurgeryDyslipidemiaRespirology
researchProduct

Circulating leukocyte telomere length and oxidative stress: A new target for statin therapy

2011

International audience; Objectives: We investigated the relationship between prior statin therapy and leukocyte telomere length (LTL), as well as their interaction with potential new biomarkers of oxidative deoxyribonucleic acid (DNA) lesions and reactive oxygen species-induced inflammation.Methods and results: From patients admitted for an acute myocardial infarction, LTL was assessed by quantitative polymerase chain reaction (Q-PCR), and leukocyte Finkel-Biskis-Jinkins osteosarcoma (FOS) and 8-oxoguanine DNA glycosylase (OGG1) messenger ribonucleic acid (mRNA) levels were measured by retrotranscription Q-PCR. Patients under prior chronic statin therapy were compared with patients without …

OncologyMaleMyocardial Infarction030204 cardiovascular system & hematologymedicine.disease_causeDNA Glycosylases0302 clinical medicineRisk FactorsLeukocytesMyocardial infarctionComputingMilieux_MISCELLANEOUSAged 80 and over0303 health sciencesReverse Transcriptase Polymerase Chain ReactionConfoundingMiddle AgedTelomere3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemReal-time polymerase chain reactionOsteosarcomaFemalemedicine.symptomCardiology and Cardiovascular MedicineProto-Oncogene Proteins c-fosGenetic Markersmedicine.medical_specialtyStatinmedicine.drug_classInflammationReal-Time Polymerase Chain ReactionRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansRNA MessengerPropensity Score030304 developmental biologyAgedDyslipidemiasChi-Square Distributionbusiness.industrystatinoxidative stress 2medicine.diseaseLeukocyte telomere lengthSurgeryOxidative StressLogistic ModelsinflammationLinear ModelsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessChi-squared distributionOxidative stress
researchProduct

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

2017

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is…

PhytochemicalsMedicine (miscellaneous)030204 cardiovascular system & hematologyPharmacologyIntestinal absorption0302 clinical medicineRisk FactorsDrug Interactions030212 general & internal medicineRandomized Controlled Trials as TopicNutrition and DieteticsEvidence-Based MedicineOrvostudományok3. Good healthObservational Studies as TopicLiverCardiovascular DiseasesFatty Acids Unsaturatedlipids (amino acids peptides and proteins)nutraceuticalposition papermedicine.medical_specialtyStatinCombination therapymedicine.drug_classKlinikai orvostudományok03 medical and health sciencesMeta-Analysis as TopiclipidmedicineHumansIntensive care medicineLife StyleTriglyceridesDyslipidemiasbusiness.industryProbioticsdyslipidemiaCholesterol HDLEvidence-based medicineCholesterol LDLmedicine.diseaseResidual riskIntestinal AbsorptionrecommendationsDietary SupplementsPosition paperObservational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity.

2017

Position statementAdultMaleSpanish Society for the Study of ObesityPALABRASPediatricsmedicine.medical_specialtyPediatric ObesityMEDLINEBariatric SurgeryComorbidity030204 cardiovascular system & hematologyModels BiologicalComorbidities03 medical and health sciencesDisease susceptibility0302 clinical medicineSleep Apnea SyndromesDiabetes mellitusDiagnosismedicinePrevalenceHumans030212 general & internal medicineObesityChildExerciseAdiposityDyslipidemiasInflammationbusiness.industryPreventionmedicine.diseaseObesityComorbidityDietTreatmentDiabetes Mellitus Type 2Cardiovascular DiseasesSpainBody CompositionFemaleAnti-Obesity AgentsDisease SusceptibilitybusinessEnergy IntakeEndocrinologia, diabetes y nutricion
researchProduct

Low physical activity and its association with diabetes and other cardiovascular risk factors: a nationwide, population-based study

2016

Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM; ISCIII Ministerio de Ciencia e Innovacion); Ministerio de Sanidad y Consumo; Spanish Diabetes Society (SED)

QuestionnairesMaleDislipidemiasCross-sectional studyEstudios transversalesEspañaObesidadÍndice de masa corporalBiochemistryBody Mass Index0302 clinical medicineEndocrinology:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Movement::Motor Activity [Medical Subject Headings]Public and Occupational Healthlcsh:Science:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diet Mediterranean [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]:Chemicals and Drugs::Lipids::Glycerides::Triglycerides [Medical Subject Headings]:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]Aged 80 and overDiabetis:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Lipid Metabolism Disorders::Dyslipidemias [Medical Subject Headings]:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Overweight::Obesity::Obesity Abdominal [Medical Subject Headings]Cardiovascular DiseasesObesitatEnfermedades cardiovascularesFactores de riesgomedicine.medical_specialtyEndocrine Disorders:Chemicals and Drugs::Lipids::Lipoproteins::Lipoproteins HDL::Cholesterol HDL [Medical Subject Headings]:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking [Medical Subject Headings]QüestionarisTriglicéridosExercici -- Aspectes sanitaris03 medical and health sciencesDiabetes MellitusHumans:Diseases::Cardiovascular Diseases [Medical Subject Headings]ExerciseAgedSurvey ResearchMalalties cardiovascularsPreventionlcsh:REnfermedad crónicaBiology and Life SciencesPhysical ActivityInsulin-resistancemedicine.diseaseActividad motoraObesityLipid metabolismCross-Sectional StudiesDyslipidemiaAdherenceGlucosalcsh:QBody mass indexDyslipidemiaDemography:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style::Sedentary Lifestyle [Medical Subject Headings]PhysiologyPhysical fitnessSistema cardiovascular -- Malalties:Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose [Medical Subject Headings]lcsh:Medicine:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Overweight::Obesity [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]Obesidad abdominalGeographical LocationsGlucose MetabolismRisk FactorsHábito de fumarMedicine and Health SciencesPrevalence030212 general & internal medicinePrediabetes:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]Multidisciplinary:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings]DiabetesMiddle Aged:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings]EuropeEncuestas y cuestionariosPhysiological ParametersResearch DesignCarbohydrate MetabolismFemaleResearch ArticleAdultAdolescent030209 endocrinology & metabolismVida sedentariaResearch and Analysis MethodsHDL-colesterolYoung AdultSex FactorsDiabetes mellitusmedicineAdultsObesityEspanya:Diseases::Endocrine System Diseases::Diabetes Mellitus::Prediabetic State [Medical Subject Headings]Sedentary lifestylebusiness.industryEstado prediabéticoBody WeightPhysical fitnessDieta mediterráneaMetabolisme dels lípidsDietMetabolismSpainMetabolic DisordersPeople and PlacesPhysical therapySedentary BehaviorbusinessPrevalenciaCondició física
researchProduct

NEXT GENERATION SEQUENCIN: A NEW METHODOLOGICAL APPROACH FOR THE MOLECULAR DIAGNOSIS OF GENETIC DYSLIPIDEMIAS

2014

Settore MED/09 - Medicina InternaNGS DYSLIPIDEMIAS
researchProduct

The Role of Nutraceuticals in Statin Intolerant Patients.

2018

Abstract Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activ…

Statinmedicine.drug_classDiseasecardiovascular risk ; dyslipidemia ; nutraceuticals ; position paper ; statin intolerance030204 cardiovascular system & hematologyBioinformaticsKlinikai orvostudományok03 medical and health sciences0302 clinical medicineNutraceuticalEzetimibeStatin intoleranceRed yeast riceMedicineHumansPosition paper030212 general & internal medicineEndothelial dysfunctionDyslipidemiasbusiness.industryClinical Studies as TopicOrvostudományokmedicine.diseaseCardiovascular risk3. Good healthDyslipidemiaDietary SupplementsArterial stiffnesslipids (amino acids peptides and proteins)nutraceuticalHydroxymethylglutaryl-CoA Reductase InhibitorNutraceuticalsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaposition papermedicine.drugstatin intoleranceHuman
researchProduct

Worldwide burden of LDL cholesterol: Implications in cardiovascular disease

2020

Abstract Background and aim an increased value of low-density lipoprotein cholesterol (LDL-C) is now universally considered a major cardiovascular disease (CVD) risk factor. LDL-C is included in the vast majority of worldwide cardiovascular risk prediction algorithms, as well as in the guidelines for cardiovascular risk prevention. We aimed to provide an overview of the worldwide adverse healthcare impact of low-density lipoprotein cholesterol (LDL-C). Methods and results Data on the epidemiologic burden of LDL-C >1.3 mmol/L were retrieved from Global Health Data Exchange (GHDx) registry. The current burden is 94.92 million disability-adjusted life years (DALYs), with an exponential increas…

Time FactorsDatabases FactualHealth StatusEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologyGlobal HealthRisk Assessment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsEnvironmental healthHealth careGlobal healthHumansMedicineRegistriesRisk factorEpidemicsAtherosclerosis; Cardiovascular disease; Cholesterol; Low-density lipoproteinsDyslipidemiasLdl cholesterolNutrition and Dieteticsbusiness.industryCholesterolCholesterol LDLAtherosclerosisCardiovascular diseaseUp-RegulationPrediction algorithmsCholesterolchemistryCardiovascular DiseasesLow-density lipoproteinslipids (amino acids peptides and proteins)Risk preventionQuality-Adjusted Life YearsCardiology and Cardiovascular MedicinebusinessBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Pat…

2018

: Obesity predisposes for atrial fibrillation, heart failure, sudden cardiac death, renal disease and ischemic stroke, which are the main causes of cardiovascular hospitalization and mortality. As obesity and the cardiovascular effects on the vessels and the heart start early in life, even from childhood, it is important for health policies to prevent obesity very early before the disease manifestation emerge. Key roles in the prevention are strategies to increase physical exercise, reduce body weight and to prevent or treat hypertension, lipids disorders and diabetes earlier and efficiently to prevent cardiovascular complications.

adolescent hypertensioncardiovascular riskmedicine.medical_specialtyBiomedical ResearchConsensusPhysiologyheart failurePhysical exerciseDisease030204 cardiovascular system & hematologysudden cardiac deathSudden cardiac death03 medical and health sciencesbody weight0302 clinical medicineRisk FactorsDiabetes mellitusWeight LossMetabolically healthy obesityDiabetes MellitusInternal MedicinemedicineHumansatrial fibrillation030212 general & internal medicineObesityIntensive care medicineExerciseStrokeDyslipidemiasdiabetesbusiness.industrydyslipidemiacardiorespiratory fitnemedicine.diseaseObesityStrokediabeteCardiovascular DiseasesHeart failureHypertensionmetabolically healthy obesityCardiology and Cardiovascular Medicinebusinesschronic kidney disease
researchProduct